Updates are available Correction dated 2025-05-07

Article History

Received: 10 December 2024

Accepted: 14 January 2025

First Online: 4 February 2025

Change Date: 7 May 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13555-025-01420-3

Declarations

:

: Diamant Thaçi has been a consultant and an adviser and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for the following companies: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Galderma, Janssen-Cilag, LEO Pharma A/S, L’Oreal, Meiji, Newbridge, Novartis, Regeneron, Sanofi, Sun Pharma, Pfizer, Target RWE, UCB, and Vichy. He has received grants from AbbVie, LEO Pharma A/S, and Novartis. Mamitaro Ohtsuki has received honoraria or fees for serving on advisory boards or speakers' bureaus, fees for consulting, and grants for investigator activities from AbbVie, Amgen, BI, BMS, Celgene, Eisai, Janssen, Kyowa Kirin, LEO, Lilly, Maruho, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sun Pharma, Taiho, Torii, and UCB. Julia-Tatjana Maul has served as an adviser and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, and UCB. Andrea Szegedi has received a research grant from AbbVie and lecture and/or consultant fees from Celgene, Eli Lilly, Janssen Pharmaceutical, LEO Pharma, AbbVie, Novartis, MSD, Pfizer, UCB, Galderma, and Sanofi. Paula C. Luna has received consulting fees, honoraria, or grant support or lecturing fees from Pierre Fabre Laboratory, Beiersdorf, Laboratoire La Roche Posay, Sanofi–Genzyme, AbbVie, Novartis, Janssen, Pfizer, Elli Lilly, Boehringer Ingelheim, Takeda, Bristol Myers Squibb, Galderma, and GlaxoSmithKline. Dr. Charles W. Lynde has been a speaker and/or consultant for AbbVie, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Eli Lilly, Fresnius Kabi, Galderma, GSK, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L'Oreal, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, SunPharma,TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. He has been a principal investigator for AbbVie, Acelyrin, Akros, Altius, Amgen, Aralez, Arcutis, Avillion, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, Dermavant, Devonian, Eli Lilly, Evelo, Galderma, GSK, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L'Oreal, Medexus, MedX, Merck, MoonLake, Nimbus, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, SunPharma, Takeda, TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. Ahmed M. Soliman, Hongwei Wang, Christian Kaufmann, Doug A. Ashley, Tshepiso Madihlaba, and Simone Rubant are employees of AbbVie and may own stock, stock options, or patents. Kim A. Papp has received honoraria and/or grants from and is a consultant, investigator, or a scientific officer for AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Eli Lilly and Company, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB Pharma, and Zai Lab. Orcid: 0000–0001-9557–3642.

: This post-marketing observational study was conducted following the protocol and applicable local guidelines and regulations. Approvals were obtained from local ethics committees of the relevant countries, and the patients provided written informed consent at study initiation. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki.